Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute hea...
Uložené v:
| Vydané v: | The Lancet (British edition) Ročník 400; číslo 10367; s. 1938 - 1952 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Elsevier Ltd
03.12.2022
Elsevier Limited Elsevier |
| Predmet: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.
In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.
Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9–13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50–0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group.
An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.
Roche Diagnostics. |
|---|---|
| AbstractList | There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.
In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.
Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9–13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50–0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group.
An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.
Roche Diagnostics. Summary Background There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. Methods In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete. Findings Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9–13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50–0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group. Interpretation An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care. Funding Roche Diagnostics. BackgroundThere is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.MethodsIn this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.FindingsBetween May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9–13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50–0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group.InterpretationAn intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.FundingRoche Diagnostics. There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.BACKGROUNDThere is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18-85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.METHODSIn this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18-85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9-13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50-0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group.FINDINGSBetween May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9-13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50-0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group.An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.INTERPRETATIONAn intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.Roche Diagnostics.FUNDINGRoche Diagnostics. |
| Author | Celutkiene, Jelena Davison, Beth Sliwa, Karen Saidu, Hadiza Takagi, Koji Cotter, Gad Filippatos, Gerasimos Cohen-Solal, Alain Ponikowski, Piotr Damasceno, Albertino Voors, Adriaan A Pang, Peter S Chioncel, Ovidiu Novosadova, Maria Gayat, Etienne Mebazaa, Alexandre Diaz, Rafael Metra, Marco Edwards, Christopher |
| Author_xml | – sequence: 1 givenname: Alexandre surname: Mebazaa fullname: Mebazaa, Alexandre email: alexandre.mebazaa@aphp.fr organization: Université Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France – sequence: 2 givenname: Beth surname: Davison fullname: Davison, Beth organization: Université Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France – sequence: 3 givenname: Ovidiu surname: Chioncel fullname: Chioncel, Ovidiu organization: Emergency Institute for Cardiovascular Diseases “Prof C C Iliescu”, University of Medicine “Carol Davila”, Bucharest, Romania – sequence: 4 givenname: Alain surname: Cohen-Solal fullname: Cohen-Solal, Alain organization: Université Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France – sequence: 5 givenname: Rafael surname: Diaz fullname: Diaz, Rafael organization: Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina – sequence: 6 givenname: Gerasimos surname: Filippatos fullname: Filippatos, Gerasimos organization: National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece – sequence: 7 givenname: Marco surname: Metra fullname: Metra, Marco organization: Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy – sequence: 8 givenname: Piotr surname: Ponikowski fullname: Ponikowski, Piotr organization: Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland – sequence: 9 givenname: Karen surname: Sliwa fullname: Sliwa, Karen organization: Division of Cardiology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa – sequence: 10 givenname: Adriaan A surname: Voors fullname: Voors, Adriaan A organization: Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands – sequence: 11 givenname: Christopher surname: Edwards fullname: Edwards, Christopher organization: Momentum Research, Durham, NC, USA – sequence: 12 givenname: Maria surname: Novosadova fullname: Novosadova, Maria organization: Momentum Research, Durham, NC, USA – sequence: 13 givenname: Koji surname: Takagi fullname: Takagi, Koji organization: Momentum Research, Durham, NC, USA – sequence: 14 givenname: Albertino surname: Damasceno fullname: Damasceno, Albertino organization: Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique – sequence: 15 givenname: Hadiza surname: Saidu fullname: Saidu, Hadiza organization: Murtala Muhammed Specialist Hospital, Bayero University Kano, Kano, Nigeria – sequence: 16 givenname: Etienne surname: Gayat fullname: Gayat, Etienne organization: Université Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France – sequence: 17 givenname: Peter S surname: Pang fullname: Pang, Peter S organization: Department of Emergency Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA – sequence: 18 givenname: Jelena surname: Celutkiene fullname: Celutkiene, Jelena organization: Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania – sequence: 19 givenname: Gad surname: Cotter fullname: Cotter, Gad organization: Université Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36356631$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-03934196$$DView record in HAL |
| BookMark | eNqNkl2LEzEYhQdZcT_0JygBb7rQ0WTyMdMVkWVxt0Jxwa7gXUiTd2zWdFKTzEJ_lP_RTLv2ojfrVRJ4zuHNec9pcdT5DoriNcHvCCbi_RwThktRUzGqqnNc4VqU5FlxQljNSs7qH0fFyR45Lk5jvMcYM4H5i-KYCsqFoOSk-DNXLaTNGCXvIKiFdTZtkOoMgra1WukN8i3q12WyKahkfTe8f_bWgLMdlMYG0AkMWoHJuENpmW3WFiJqfUBK9wnQElRIqFXW9QHQaH737fbrTTm9Pr9ACq16l2y3tVZujPwautKpBeR7yHP4lY1g8nzBKveyeN4qF-HV43lWfL_-fHc1LWe3N1-uLmel5pSkkuYQuBFYMS4MBmF4zVkl6KTW9YQKUTWNwtzoRYNJI6BlWuiWKkMmBFSrF_SsGO98l8rJdbArFTbSKyunlzNpuwhhJTGdUEYm4oFkfLTD18H_7iEmmYfW4JzqwPdRVjXljeC4aTL69gC9933IPx8oxgTjpKaZevNI9Ysc7H6Ef3vLAN8BOvgYA7R7hGA59ENu-yGH5cuqktt-yEH34UCnbdpmn7dr3ZPqTzs15OwfLAQZtYVOw64F0nj7pMPHAwedazQU5xds_kP_F-xC5tw |
| CitedBy_id | crossref_primary_10_1016_j_jchf_2023_07_022 crossref_primary_10_1093_ndt_gfae258 crossref_primary_10_1093_eurheartj_ehaf218 crossref_primary_10_3390_jcdd12050182 crossref_primary_10_1136_heartjnl_2022_321757 crossref_primary_10_1002_jhm_13250 crossref_primary_10_1016_j_jacadv_2023_100819 crossref_primary_10_1002_jhm_13374 crossref_primary_10_1016_S0140_6736_23_02679_X crossref_primary_10_1093_eurheartj_ehad395 crossref_primary_10_3390_diagnostics14020131 crossref_primary_10_1055_a_2461_7287 crossref_primary_10_1161_JAHA_123_032296 crossref_primary_10_1007_s12181_023_00611_6 crossref_primary_10_1161_CIRCHEARTFAILURE_125_013274 crossref_primary_10_1016_j_jacadv_2023_100818 crossref_primary_10_1016_j_mmm_2025_01_005 crossref_primary_10_1136_bmjopen_2023_073455 crossref_primary_10_36290_vnl_2023_008 crossref_primary_10_1002_tre_948 crossref_primary_10_1016_j_jchf_2023_07_014 crossref_primary_10_3390_diagnostics15050540 crossref_primary_10_1097_FJC_0000000000001532 crossref_primary_10_12968_bjca_2024_0021 crossref_primary_10_3390_diagnostics14192251 crossref_primary_10_1016_j_amjmed_2023_10_013 crossref_primary_10_1016_j_jchf_2024_09_020 crossref_primary_10_1093_eurheartj_ehae111 crossref_primary_10_1556_650_2024_33081 crossref_primary_10_1093_eurheartj_ehad150 crossref_primary_10_1016_j_hfc_2024_06_008 crossref_primary_10_5334_gh_1449 crossref_primary_10_1007_s12325_023_02502_4 crossref_primary_10_1016_j_hfc_2024_06_004 crossref_primary_10_1016_j_jacc_2025_05_040 crossref_primary_10_1136_heartjnl_2024_325562 crossref_primary_10_1016_j_hfc_2024_06_002 crossref_primary_10_1016_j_hfc_2025_01_003 crossref_primary_10_1136_heartjnl_2022_321764 crossref_primary_10_1016_j_jacc_2024_09_004 crossref_primary_10_1016_j_japhpi_2025_100056 crossref_primary_10_1016_j_jchf_2024_02_020 crossref_primary_10_1177_08850666241303461 crossref_primary_10_3390_jcm12113834 crossref_primary_10_1016_j_cardfail_2024_09_002 crossref_primary_10_1159_000538601 crossref_primary_10_1093_eurheartj_ehaf358 crossref_primary_10_1093_eurheartj_ehaf480 crossref_primary_10_1016_j_jchf_2024_01_011 crossref_primary_10_1016_j_jchf_2024_10_014 crossref_primary_10_1002_ehf2_14275 crossref_primary_10_1016_j_jchf_2024_08_004 crossref_primary_10_1016_j_mayocp_2024_12_005 crossref_primary_10_1093_eurheartj_ehaf229 crossref_primary_10_1093_eurheartj_ehad169 crossref_primary_10_1161_CIRCHEARTFAILURE_123_010540 crossref_primary_10_1161_CIRCOUTCOMES_124_011684 crossref_primary_10_1016_j_jacc_2025_04_022 crossref_primary_10_1016_j_jchf_2024_01_003 crossref_primary_10_1253_circj_CJ_25_0200 crossref_primary_10_1016_j_jchf_2023_06_003 crossref_primary_10_1055_a_2047_5013 crossref_primary_10_1111_imj_16378 crossref_primary_10_1016_j_jchf_2025_03_010 crossref_primary_10_1016_j_jjcc_2023_07_019 crossref_primary_10_1016_j_hlc_2024_11_021 crossref_primary_10_1002_ejhf_3024 crossref_primary_10_1016_j_jchf_2025_03_014 crossref_primary_10_1016_j_jchf_2024_08_017 crossref_primary_10_1016_j_jacc_2024_09_022 crossref_primary_10_1016_j_shj_2023_100187 crossref_primary_10_3390_biomedicines13081846 crossref_primary_10_1016_j_hlc_2023_11_029 crossref_primary_10_1038_s41569_023_00841_x crossref_primary_10_1093_ndt_gfae058 crossref_primary_10_15829_15604071_2024_5915 crossref_primary_10_1093_eurheartj_ehad356 crossref_primary_10_1016_j_jchf_2025_02_006 crossref_primary_10_1016_j_hlc_2025_06_002 crossref_primary_10_1093_eurheartj_ehae561 crossref_primary_10_1016_j_hlc_2023_08_002 crossref_primary_10_1016_j_jacc_2024_04_055 crossref_primary_10_1016_j_cardfail_2023_08_017 crossref_primary_10_1161_JAHA_124_034793 crossref_primary_10_36290_vnl_2024_005 crossref_primary_10_1007_s12181_023_00655_8 crossref_primary_10_1016_j_jdiacomp_2022_108389 crossref_primary_10_1007_s11936_024_01048_0 crossref_primary_10_1016_j_jchf_2025_03_045 crossref_primary_10_1016_j_jacc_2023_07_024 crossref_primary_10_1111_eci_14163 crossref_primary_10_1016_j_jchf_2022_12_008 crossref_primary_10_1016_j_jchf_2023_08_027 crossref_primary_10_36290_vnl_2025_047 crossref_primary_10_1016_j_pcad_2024_01_008 crossref_primary_10_1016_j_pcad_2024_01_009 crossref_primary_10_1080_14737159_2023_2216386 crossref_primary_10_15829_1560_4071_2024_6162 crossref_primary_10_1161_JAHA_124_036998 crossref_primary_10_1016_j_cardfail_2022_12_005 crossref_primary_10_1007_s40256_024_00652_6 crossref_primary_10_1016_j_cardfail_2025_02_014 crossref_primary_10_3390_jpm13061015 crossref_primary_10_1016_j_jchf_2024_10_007 crossref_primary_10_1055_a_2447_7654 crossref_primary_10_1016_j_jchf_2025_02_023 crossref_primary_10_7759_cureus_83017 crossref_primary_10_1136_dtb_2024_000050 crossref_primary_10_1016_j_jchf_2025_02_020 crossref_primary_10_1161_CIRCHEARTFAILURE_124_012716 crossref_primary_10_1007_s00392_023_02241_0 crossref_primary_10_1016_j_jacc_2023_02_029 crossref_primary_10_1161_CIRCHEARTFAILURE_124_011627 crossref_primary_10_15829_1728_8800_2024_4100 crossref_primary_10_1016_j_jchf_2024_09_013 crossref_primary_10_1016_j_jchf_2024_09_010 crossref_primary_10_1016_j_jacc_2024_05_079 crossref_primary_10_1016_j_jchf_2024_09_018 crossref_primary_10_1016_j_jchf_2024_09_017 crossref_primary_10_1016_j_ijcard_2023_05_007 crossref_primary_10_1093_eurjcn_zvaf161 crossref_primary_10_1016_j_ijcard_2023_131118 crossref_primary_10_1080_03007995_2025_2480736 crossref_primary_10_1093_eurheartj_ehaf668 crossref_primary_10_1093_eurheartj_ehae334 crossref_primary_10_1136_bmjopen_2023_076519 crossref_primary_10_1016_j_jclinane_2025_111824 crossref_primary_10_1007_s11883_024_01197_4 crossref_primary_10_1253_circj_CJ_25_0002 crossref_primary_10_1093_ehjopen_oead100 crossref_primary_10_1016_j_amjms_2025_01_009 crossref_primary_10_1016_j_repc_2024_12_004 crossref_primary_10_1016_j_jacadv_2025_101753 crossref_primary_10_1016_j_diabet_2025_101645 crossref_primary_10_3390_medicina61050816 crossref_primary_10_1007_s40256_025_00729_w crossref_primary_10_1016_j_jacasi_2025_03_004 crossref_primary_10_3390_ph16121740 crossref_primary_10_1097_MEJ_0000000000001151 crossref_primary_10_1097_MEJ_0000000000001152 crossref_primary_10_1093_eurjcn_zvae139 crossref_primary_10_1007_s10741_024_10412_y crossref_primary_10_1007_s10741_025_10512_3 crossref_primary_10_1080_00365521_2023_2183734 crossref_primary_10_7759_cureus_51756 crossref_primary_10_1016_j_jchf_2024_03_001 crossref_primary_10_1038_s41598_024_60011_y crossref_primary_10_1007_s15027_024_3623_y crossref_primary_10_1161_JAHA_125_042943 crossref_primary_10_26599_1671_5411_2025_03_002 crossref_primary_10_1007_s00059_025_05330_0 crossref_primary_10_3390_jcm13072119 crossref_primary_10_3390_jcdd12080302 crossref_primary_10_1016_j_ijcard_2024_132920 crossref_primary_10_1093_eurjcn_zvae008 crossref_primary_10_3390_jcm14165883 crossref_primary_10_1161_JAHA_124_040252 crossref_primary_10_1016_j_hrtlng_2025_04_027 crossref_primary_10_1016_j_iccl_2023_11_001 crossref_primary_10_1016_j_yjmcc_2025_06_013 crossref_primary_10_1016_j_amjcard_2023_09_010 crossref_primary_10_18087_cardio_2024_2_n2554 crossref_primary_10_3390_jcm14186681 crossref_primary_10_1371_journal_pone_0309948 crossref_primary_10_1097_HCO_0000000000001021 crossref_primary_10_4102_safp_v67i1_6126 crossref_primary_10_1016_j_cardfail_2025_02_018 crossref_primary_10_3390_jcm12226956 crossref_primary_10_1016_j_jacadv_2024_101131 crossref_primary_10_1161_CIRCHEARTFAILURE_123_011221 crossref_primary_10_1016_j_medcle_2024_06_001 crossref_primary_10_1016_j_jnma_2023_11_008 crossref_primary_10_1007_s11936_023_00979_4 crossref_primary_10_4103_jicc_jicc_65_24 crossref_primary_10_1016_j_banm_2025_03_002 crossref_primary_10_1016_j_jacadv_2024_101126 crossref_primary_10_1007_s40256_024_00646_4 crossref_primary_10_1093_ehjacc_zuaf051 crossref_primary_10_3390_jcm13175264 crossref_primary_10_3390_cells14171400 crossref_primary_10_1016_j_jacadv_2024_101383 crossref_primary_10_1093_eurjcn_zvae029 crossref_primary_10_2196_63391 crossref_primary_10_1016_j_cardfail_2023_05_015 crossref_primary_10_36628_ijhf_2025_0037 crossref_primary_10_1161_CIR_0000000000001231 crossref_primary_10_36660_abcimg_20250039i crossref_primary_10_1177_14703203241306037 crossref_primary_10_1136_heartjnl_2024_324176 crossref_primary_10_1161_CIRCULATIONAHA_123_068524 crossref_primary_10_1016_j_ijcard_2025_133491 crossref_primary_10_1038_s44325_024_00028_4 crossref_primary_10_1016_j_jchf_2025_04_013 crossref_primary_10_1002_cpt_3526 crossref_primary_10_1007_s11096_024_01808_9 crossref_primary_10_1007_s11897_023_00610_4 crossref_primary_10_1016_j_cardfail_2023_12_004 crossref_primary_10_1016_j_jchf_2024_02_008 crossref_primary_10_1161_CIRCHEARTFAILURE_123_011164 crossref_primary_10_3390_jcdd12020050 crossref_primary_10_3390_jcm12123970 crossref_primary_10_1111_imj_16440 crossref_primary_10_1016_j_jacadv_2024_101024 crossref_primary_10_1177_00185787241295983 crossref_primary_10_3390_jcm12144676 crossref_primary_10_1007_s12928_025_01087_9 crossref_primary_10_1002_clc_70187 crossref_primary_10_1038_s41581_025_00931_8 crossref_primary_10_1136_heartjnl_2024_324160 crossref_primary_10_1161_CIRCULATIONAHA_124_068962 crossref_primary_10_1371_journal_pone_0328971 crossref_primary_10_1007_s11739_025_03891_w crossref_primary_10_1093_eurheartj_ehaf244 crossref_primary_10_1093_eurheartj_ehad192 crossref_primary_10_1007_s10741_025_10544_9 crossref_primary_10_1053_j_jvca_2025_08_019 crossref_primary_10_1093_eurheartj_ehad195 crossref_primary_10_1007_s11136_024_03818_6 crossref_primary_10_1016_j_nurpra_2024_104990 crossref_primary_10_1038_s41591_024_03238_6 crossref_primary_10_1002_jhm_13317 crossref_primary_10_1002_ehf2_14381 crossref_primary_10_7759_cureus_81111 crossref_primary_10_1038_s41598_025_09074_z crossref_primary_10_1097_HCO_0000000000001108 crossref_primary_10_36660_abchf_20240020i crossref_primary_10_1007_s40266_024_01166_1 crossref_primary_10_1097_CP9_0000000000000073 crossref_primary_10_1016_j_jchf_2024_03_022 crossref_primary_10_3390_life15040526 crossref_primary_10_1007_s12471_025_01949_0 crossref_primary_10_3390_jcm14165894 crossref_primary_10_1007_s11560_024_00821_3 crossref_primary_10_3390_jcdd12010025 crossref_primary_10_1161_CIRCULATIONAHA_123_067489 crossref_primary_10_1002_ejhf_2786 crossref_primary_10_1080_00015385_2024_2396767 crossref_primary_10_1007_s40256_023_00601_9 crossref_primary_10_1002_clc_70165 crossref_primary_10_1016_j_amjcard_2023_09_042 crossref_primary_10_1016_S0140_6736_23_01313_2 crossref_primary_10_1159_000531102 crossref_primary_10_3389_fendo_2025_1605746 crossref_primary_10_1093_cvr_cvae047 crossref_primary_10_3390_jcdd10090388 crossref_primary_10_1016_j_amjms_2024_06_002 crossref_primary_10_1016_j_amjmed_2023_09_018 crossref_primary_10_1016_j_jacc_2024_01_029 crossref_primary_10_2459_JCM_0000000000001581 crossref_primary_10_1002_ehf2_14363 crossref_primary_10_1016_j_bja_2024_10_003 crossref_primary_10_1161_CIRCULATIONAHA_122_063811 crossref_primary_10_1016_j_jchf_2023_03_009 crossref_primary_10_1371_journal_pdig_0000868 crossref_primary_10_1016_j_jchf_2023_03_007 crossref_primary_10_1016_j_jchf_2024_05_013 crossref_primary_10_1093_ajhp_zxaf025 crossref_primary_10_1007_s00380_024_02366_w crossref_primary_10_1093_ejcts_ezae355 crossref_primary_10_1016_j_ahj_2024_04_019 crossref_primary_10_1016_j_cpha_2024_11_002 crossref_primary_10_1016_j_jacc_2023_05_050 crossref_primary_10_2215_CJN_0000000588 crossref_primary_10_1002_ejhf_2889 crossref_primary_10_1007_s11883_024_01259_7 crossref_primary_10_1371_journal_pgph_0004544 crossref_primary_10_1016_j_jacc_2023_04_006 crossref_primary_10_1016_j_jacc_2023_12_024 crossref_primary_10_1016_j_radcr_2023_10_055 crossref_primary_10_3390_jcm14082664 crossref_primary_10_1016_j_amjcard_2024_05_015 crossref_primary_10_1016_j_nurpra_2024_105088 crossref_primary_10_1016_j_jacasi_2025_01_015 crossref_primary_10_1002_ejhf_2754 crossref_primary_10_1002_ejhf_2874 crossref_primary_10_1002_ejhf_2759 crossref_primary_10_1002_ejhf_2739 crossref_primary_10_1093_eurheartj_ehad617 crossref_primary_10_1161_JAHA_123_031745 crossref_primary_10_1016_j_jchf_2023_11_021 crossref_primary_10_1038_s41569_024_00997_0 crossref_primary_10_3389_fcvm_2023_1235178 crossref_primary_10_1007_s00059_023_05205_2 crossref_primary_10_3390_jcm13154470 crossref_primary_10_1007_s10741_025_10515_0 crossref_primary_10_1007_s10741_025_10481_7 crossref_primary_10_1016_j_jacc_2023_03_426 crossref_primary_10_3390_biomedicines13030608 crossref_primary_10_1016_j_ijcha_2025_101702 crossref_primary_10_1136_bmj_2023_078188 crossref_primary_10_1111_dom_70044 crossref_primary_10_1007_s10741_024_10389_8 crossref_primary_10_2459_JCM_0000000000001667 crossref_primary_10_1016_j_pharmthera_2025_108861 crossref_primary_10_1681_ASN_0000000000000449 crossref_primary_10_1183_13993003_01640_2024 crossref_primary_10_1007_s40266_023_01046_0 crossref_primary_10_1097_MS9_0000000000003592 crossref_primary_10_1016_j_jchf_2023_04_017 crossref_primary_10_7326_M23_2638 crossref_primary_10_1007_s00392_024_02518_y crossref_primary_10_1038_s44324_025_00068_z crossref_primary_10_1016_j_jchf_2023_04_015 crossref_primary_10_1016_j_amjcard_2023_11_005 crossref_primary_10_1016_j_ejim_2025_01_014 crossref_primary_10_1016_j_jacc_2023_03_430 crossref_primary_10_1371_journal_pone_0330188 crossref_primary_10_1136_bmj_2023_077025 crossref_primary_10_1016_j_acvd_2025_02_012 crossref_primary_10_1093_eurheartj_ehac825 crossref_primary_10_1016_j_cardfail_2025_06_012 crossref_primary_10_1055_a_1996_5873 crossref_primary_10_1016_j_cardfail_2024_12_006 crossref_primary_10_1016_j_hlc_2023_06_080 crossref_primary_10_1007_s40256_025_00730_3 crossref_primary_10_1016_j_ejim_2023_04_011 crossref_primary_10_1016_j_ijcard_2025_133367 crossref_primary_10_1016_j_jchf_2024_04_005 crossref_primary_10_1183_13993003_01344_2024 crossref_primary_10_1093_eurjpc_zwad151 crossref_primary_10_1159_000543931 crossref_primary_10_1016_j_cardfail_2025_06_003 crossref_primary_10_1186_s12872_024_03728_y crossref_primary_10_1001_jamainternmed_2024_1523 crossref_primary_10_1253_circj_CJ_24_1020 crossref_primary_10_1016_j_cardfail_2023_10_485 crossref_primary_10_1016_j_cardfail_2025_06_002 crossref_primary_10_1016_j_cardfail_2024_12_016 crossref_primary_10_1016_j_cpcardiol_2024_102779 crossref_primary_10_1016_j_jjcc_2023_10_006 crossref_primary_10_1093_eurjpc_zwae114 crossref_primary_10_1016_j_jjcc_2023_10_009 crossref_primary_10_1161_JAHA_122_029071 crossref_primary_10_15829_1560_4071_2023_5621 crossref_primary_10_1016_j_jchf_2024_04_017 crossref_primary_10_1007_s10557_025_07714_0 crossref_primary_10_1002_ejhf_2833 crossref_primary_10_1016_j_ancard_2025_101933 crossref_primary_10_1002_ejhf_2955 crossref_primary_10_1016_j_athoracsur_2024_05_034 crossref_primary_10_33678_cor_2024_025 crossref_primary_10_1016_j_ccl_2023_06_007 crossref_primary_10_1016_j_ccl_2023_06_006 crossref_primary_10_1016_j_ancard_2023_101680 crossref_primary_10_3390_jcm14010139 crossref_primary_10_1007_s11886_024_02101_x crossref_primary_10_1136_conmed_2024_000013 crossref_primary_10_1007_s10741_023_10325_2 crossref_primary_10_1007_s11739_024_03791_5 crossref_primary_10_3390_biomedicines12050951 crossref_primary_10_3390_biomedicines12112560 crossref_primary_10_1093_eurjpc_zwad170 crossref_primary_10_1016_j_ccl_2023_06_001 crossref_primary_10_15829_1560_4071_2024_5841 crossref_primary_10_1007_s10741_024_10468_w crossref_primary_10_1016_j_jchf_2024_05_028 crossref_primary_10_1161_CIRCHEARTFAILURE_125_013417 crossref_primary_10_1016_j_jchf_2024_05_024 crossref_primary_10_1007_s13300_025_01725_8 crossref_primary_10_1016_j_amjmed_2024_10_015 crossref_primary_10_1007_s00380_025_02525_7 crossref_primary_10_4103_heartviews_heartviews_152_24 crossref_primary_10_1159_000544817 crossref_primary_10_1016_j_clinme_2025_100296 crossref_primary_10_1016_j_cjca_2023_06_430 crossref_primary_10_1007_s11517_024_03174_0 crossref_primary_10_1159_000540453 crossref_primary_10_1007_s40140_023_00595_9 crossref_primary_10_1007_s12181_024_00716_6 crossref_primary_10_1016_j_jchf_2023_05_012 crossref_primary_10_1016_j_ihj_2024_04_004 crossref_primary_10_1007_s11897_023_00594_1 crossref_primary_10_1093_eurjpc_zwae162 crossref_primary_10_3390_jcm13102775 crossref_primary_10_1016_j_mcna_2025_04_010 crossref_primary_10_1007_s11886_024_02175_7 crossref_primary_10_1016_j_cardfail_2025_05_005 crossref_primary_10_1016_j_mcna_2025_04_012 crossref_primary_10_1007_s10741_024_10419_5 crossref_primary_10_1016_j_pcad_2025_04_001 crossref_primary_10_1007_s10741_025_10486_2 crossref_primary_10_3390_jcm14113993 crossref_primary_10_1093_ehjcvp_pvad088 crossref_primary_10_1016_j_ijcrp_2024_200284 crossref_primary_10_1016_j_jchf_2025_102534 crossref_primary_10_1055_a_1949_1873 crossref_primary_10_1007_s11606_025_09515_5 crossref_primary_10_15829_1560_4071_2024_5940 crossref_primary_10_1161_CIRCULATIONAHA_123_068066 crossref_primary_10_1186_s40780_024_00357_7 crossref_primary_10_1093_eurjpc_zwaf483 crossref_primary_10_1016_j_lpm_2023_104184 crossref_primary_10_3390_jcm12031020 crossref_primary_10_1080_03007995_2024_2318002 crossref_primary_10_1093_eurheartj_ehad540 crossref_primary_10_1016_j_ijcrp_2023_200213 crossref_primary_10_1016_j_cardfail_2025_05_001 crossref_primary_10_1161_CIRCHEARTFAILURE_122_010309 crossref_primary_10_1007_s12181_023_00643_y crossref_primary_10_1177_08971900241262382 crossref_primary_10_1186_s42269_024_01251_w crossref_primary_10_1016_j_lanwpc_2023_100988 crossref_primary_10_1007_s10741_024_10471_1 crossref_primary_10_1016_j_revmed_2022_12_007 crossref_primary_10_1016_j_ejim_2024_10_024 crossref_primary_10_1016_j_cardfail_2023_09_002 crossref_primary_10_1016_j_cardfail_2023_09_005 crossref_primary_10_1016_j_jchf_2023_05_034 crossref_primary_10_1007_s40265_023_01887_4 crossref_primary_10_1016_j_lpm_2023_104192 crossref_primary_10_1016_j_ejim_2024_02_028 crossref_primary_10_1093_eurheartj_ehad335 crossref_primary_10_3390_jcm14155371 crossref_primary_10_3390_jcm14103611 crossref_primary_10_1016_j_jacadv_2023_100316 crossref_primary_10_1016_j_jacadv_2025_101607 crossref_primary_10_1007_s13300_025_01796_7 crossref_primary_10_1016_j_ancard_2023_101640 crossref_primary_10_1016_j_jchf_2025_01_010 crossref_primary_10_1038_s41591_023_02567_2 crossref_primary_10_3390_jcm13092501 crossref_primary_10_3390_jcm13123485 crossref_primary_10_1016_j_ancard_2024_101802 crossref_primary_10_1016_j_jacc_2024_05_030 crossref_primary_10_1016_j_jchf_2023_10_011 crossref_primary_10_1093_ehjcvp_pvaf040 crossref_primary_10_1016_j_ancard_2023_101646 crossref_primary_10_1016_j_nurpra_2024_105108 crossref_primary_10_1093_ehjdh_ztaf004 crossref_primary_10_1080_14796678_2025_2490403 crossref_primary_10_1093_eurheartj_ehad444 crossref_primary_10_1016_j_jchf_2022_11_019 crossref_primary_10_1093_ehjqcco_qcae086 crossref_primary_10_1161_CIRCULATIONAHA_124_070228 crossref_primary_10_3389_fcvm_2024_1350846 crossref_primary_10_3390_biomedicines11082208 crossref_primary_10_1007_s10741_025_10496_0 crossref_primary_10_1016_j_ijcard_2024_132261 crossref_primary_10_1002_jppr_70014 crossref_primary_10_1016_j_ijcha_2025_101797 crossref_primary_10_1016_j_ihj_2024_07_005 crossref_primary_10_1016_j_jacc_2023_03_393 crossref_primary_10_7759_cureus_92735 crossref_primary_10_3390_clinpract13050090 crossref_primary_10_12968_bjca_2025_0021 crossref_primary_10_4330_wjc_v17_i6_107102 crossref_primary_10_1097_JCN_0000000000001068 crossref_primary_10_1016_j_cardfail_2025_04_006 crossref_primary_10_1016_j_jacc_2023_04_057 crossref_primary_10_1016_j_cardfail_2025_04_008 crossref_primary_10_1016_j_rec_2023_10_009 crossref_primary_10_1016_j_repc_2024_08_009 crossref_primary_10_1093_ehjdh_ztaf079 crossref_primary_10_1016_j_accpm_2025_101481 crossref_primary_10_1016_j_amjcard_2025_08_022 crossref_primary_10_1007_s10741_025_10497_z crossref_primary_10_1177_10600280241277354 crossref_primary_10_1371_journal_pone_0323952 crossref_primary_10_1016_S0140_6736_22_02372_8 crossref_primary_10_3390_jcm13020311 crossref_primary_10_1093_eurheartj_ehac781 crossref_primary_10_1093_ehjcvp_pvae096 crossref_primary_10_1136_heartjnl_2022_322001 crossref_primary_10_1016_j_jchf_2024_06_013 crossref_primary_10_3390_jcdd10030114 crossref_primary_10_1016_j_cardfail_2024_02_001 crossref_primary_10_3389_fcvm_2023_1193226 crossref_primary_10_1093_ehjcvp_pvaf061 crossref_primary_10_1016_j_jchf_2024_06_010 crossref_primary_10_1016_j_jchf_2023_06_010 crossref_primary_10_1016_j_jchf_2025_102615 crossref_primary_10_1007_s40256_024_00660_6 crossref_primary_10_3390_jcm14103522 crossref_primary_10_1016_S0140_6736_23_02677_6 crossref_primary_10_3390_jcm13206274 crossref_primary_10_1093_ehjopen_oeae054 crossref_primary_10_1111_dom_16388 crossref_primary_10_1111_aas_70042 crossref_primary_10_1136_heartjnl_2022_322137 crossref_primary_10_1016_j_jchf_2023_06_021 crossref_primary_10_1093_ehjdh_ztaf062 crossref_primary_10_1089_jpm_2023_0681 crossref_primary_10_1161_CIRCULATIONAHA_124_073521 crossref_primary_10_1161_CIRCULATIONAHA_124_070251 crossref_primary_10_1016_j_ahj_2025_06_001 crossref_primary_10_3390_ijms25031574 crossref_primary_10_1161_JAHA_124_037899 crossref_primary_10_1007_s42399_025_02034_8 crossref_primary_10_1007_s10741_025_10518_x crossref_primary_10_1016_j_jchf_2024_07_009 crossref_primary_10_3390_ijms25063113 crossref_primary_10_15212_CVIA_2025_0005 crossref_primary_10_1016_j_jchf_2025_102515 crossref_primary_10_1080_14796678_2025_2503666 crossref_primary_10_14797_mdcvj_1416 crossref_primary_10_1007_s11886_023_01907_5 crossref_primary_10_1016_j_amjcard_2025_07_005 crossref_primary_10_1016_j_mcna_2025_04_008 crossref_primary_10_1093_ehjqcco_qcaf095 crossref_primary_10_1038_s41591_024_03265_3 crossref_primary_10_1016_j_mcna_2025_04_001 crossref_primary_10_1001_jamanetworkopen_2024_46684 crossref_primary_10_1136_openhrt_2023_002480 crossref_primary_10_1007_s12471_023_01837_5 crossref_primary_10_1007_s15006_023_2974_0 crossref_primary_10_3390_ijms25052484 crossref_primary_10_3389_fcvm_2023_1263482 crossref_primary_10_1016_j_rec_2023_03_005 crossref_primary_10_1016_S0140_6736_25_01679_4 crossref_primary_10_1016_j_acvd_2023_11_013 crossref_primary_10_7326_AITC202312190 |
| Cites_doi | 10.1002/ejhf.2333 10.1161/CIRCULATIONAHA.120.051783 10.1016/j.jacc.2021.08.064 10.1002/ejhf.2252 10.1001/jama.2017.10565 10.1002/ejhf.2103 10.1016/j.jacc.2005.04.038 10.1001/jama.289.6.712 10.1002/ehf2.13369 10.1007/s00392-016-1014-9 10.1002/ejhf.2348 10.1002/ejhf.1869 10.1038/s41591-021-01659-1 10.1002/ehf2.13223 10.1002/ejhf.2219 10.1001/jama.2021.8844 10.1001/archinternmed.2012.3310 10.1016/j.amjmed.2019.06.053 10.1016/j.amjcard.2018.01.006 10.1161/CIRCULATIONAHA.121.056824 10.1002/ejhf.2357 10.1001/jamacardio.2020.7585 10.1002/ejhf.932 10.1056/NEJMoa2030183 10.1001/jama.2019.0710 10.1002/ejhf.890 10.1001/archinternmed.2007.83 10.1016/j.jacc.2018.04.070 10.1002/ejhf.1575 10.1161/CIRCHEARTFAILURE.121.009295 10.1016/j.cardfail.2022.03.356 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. 2022. Elsevier Ltd Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. – notice: 2022. Elsevier Ltd – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 1XC |
| DOI | 10.1016/S0140-6736(22)02076-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials - QC Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection ProQuest Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1952 |
| ExternalDocumentID | oai:HAL:inserm-03934196v1 36356631 10_1016_S0140_6736_22_02076_1 S0140673622020761 |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation | Roche Diagnostics. |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD AACTN AFCTW ALIPV M41 .GJ 04C 3EH 3O- 41~ 8WZ 9DU A6W AAEJM AAKAS AAQQT AAQXK AAYXX ABDBF ABWVN ACRPL ACUHS ADMUD ADNMO ADXHL ADZCM AFFHD AFFNX AGQPQ AHHHB AHQJS AJJEV AKVCP ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD Q~Q R2- SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 88A AFKWA AJOXV AMFUW CGR CUY CVF ECM EIF NPM SDF 3V. 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 1XC |
| ID | FETCH-LOGICAL-c531t-31475d60a456d0e6d575426397c79366288a05dcb80186ef4c6cf3ad191eafcb3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 668 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000923456100023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Tue Oct 14 20:50:40 EDT 2025 Sat Sep 27 23:26:44 EDT 2025 Wed Oct 29 07:20:48 EDT 2025 Wed Feb 19 02:23:35 EST 2025 Sat Nov 29 07:26:44 EST 2025 Tue Nov 18 20:57:44 EST 2025 Sun Apr 06 06:54:48 EDT 2025 Tue Oct 14 19:30:47 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10367 |
| Language | English |
| License | Copyright © 2022 Elsevier Ltd. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c531t-31475d60a456d0e6d575426397c79366288a05dcb80186ef4c6cf3ad191eafcb3 |
| Notes | ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | http://www.thelancet.com/article/S0140673622020761/pdf |
| PMID | 36356631 |
| PQID | 2744645173 |
| PQPubID | 40246 |
| PageCount | 15 |
| ParticipantIDs | hal_primary_oai_HAL_inserm_03934196v1 proquest_miscellaneous_2735865088 proquest_journals_2744645173 pubmed_primary_36356631 crossref_primary_10_1016_S0140_6736_22_02076_1 crossref_citationtrail_10_1016_S0140_6736_22_02076_1 elsevier_sciencedirect_doi_10_1016_S0140_6736_22_02076_1 elsevier_clinicalkey_doi_10_1016_S0140_6736_22_02076_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-03 |
| PublicationDateYYYYMMDD | 2022-12-03 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier |
| References | Logeart, Berthelot, Bihry (bib8) 2022; 24 Bistola, Simitsis, Parissis (bib9) 2021; 23 DeVore, Granger, Fonarow (bib21) 2021; 326 Packer, Butler, Zannad (bib32) 2021; 144 Voors, Angermann, Teerlink (bib22) 2022; 28 Greene, Butler, Albert (bib4) 2018; 72 Carubelli, Lombardi, Specchia (bib10) 2021; 8 Kimmoun, Cotter, Davison (bib17) 2019; 21 Lam, Packer, Fonarow (bib25) 2020; 133 Granger, Kaltenbach, Fonarow (bib2) 2022; 28 Chioncel, Mebazaa, Harjola (bib1) 2017; 19 Rao, Murray, Butler (bib31) 2021; 78 Cotter, Davison, Metra (bib18) 2021; 23 Krum, Roecker, Mohacsi (bib28) 2003; 289 Bhatt, Szarek, Steg (bib23) 2021; 384 Yamaguchi, Kitai, Miyamoto (bib13) 2018; 121 Pitt, White, Nicolau (bib27) 2005; 46 Berg, Jhund, Docherty (bib29) 2021; 6 Bedrouni, Sharma, Pitt (bib26) 2022 Kimmoun, Takagi, Gall (bib15) 2021; 23 Damasceno, Mayosi, Sani (bib6) 2012; 172 Ouwerkerk, Teng, Tromp (bib11) 2020; 22 McDonagh, Metra, Adamo (bib16) 2022; 24 Miró, Müller, Martín-Sánchez (bib24) 2016; 105 Butler, Yang, Sawhney, Chakladar, Yang, Djatche (bib3) 2021; 23 Gayat, Arrigo, Littnerova (bib14) 2018; 20 Joseph, Panniyammakal, Abdullakutty (bib5) 2021; 43 Felker, Anstrom, Adams (bib12) 2017; 318 Jaarsma, van der Wal, Lesman-Leegte (bib20) 2008; 168 Van Spall, Lee, Xie (bib19) 2019; 321 Čerlinskaitė, Mebazaa, Cinotti (bib7) 2021; 8 Packer, Anker, Butler (bib30) 2021; 143 Chioncel (10.1016/S0140-6736(22)02076-1_bib1) 2017; 19 DeVore (10.1016/S0140-6736(22)02076-1_bib21) 2021; 326 Joseph (10.1016/S0140-6736(22)02076-1_bib5) 2021; 43 Damasceno (10.1016/S0140-6736(22)02076-1_bib6) 2012; 172 Felker (10.1016/S0140-6736(22)02076-1_bib12) 2017; 318 Voors (10.1016/S0140-6736(22)02076-1_bib22) 2022; 28 Cotter (10.1016/S0140-6736(22)02076-1_bib18) 2021; 23 Bhatt (10.1016/S0140-6736(22)02076-1_bib23) 2021; 384 Yamaguchi (10.1016/S0140-6736(22)02076-1_bib13) 2018; 121 Packer (10.1016/S0140-6736(22)02076-1_bib32) 2021; 144 Granger (10.1016/S0140-6736(22)02076-1_bib2) 2022; 28 Ouwerkerk (10.1016/S0140-6736(22)02076-1_bib11) 2020; 22 Rao (10.1016/S0140-6736(22)02076-1_bib31) 2021; 78 Bedrouni (10.1016/S0140-6736(22)02076-1_bib26) 2022 Greene (10.1016/S0140-6736(22)02076-1_bib4) 2018; 72 Lam (10.1016/S0140-6736(22)02076-1_bib25) 2020; 133 Van Spall (10.1016/S0140-6736(22)02076-1_bib19) 2019; 321 Gayat (10.1016/S0140-6736(22)02076-1_bib14) 2018; 20 Pitt (10.1016/S0140-6736(22)02076-1_bib27) 2005; 46 Čerlinskaitė (10.1016/S0140-6736(22)02076-1_bib7) 2021; 8 Kimmoun (10.1016/S0140-6736(22)02076-1_bib15) 2021; 23 Krum (10.1016/S0140-6736(22)02076-1_bib28) 2003; 289 Miró (10.1016/S0140-6736(22)02076-1_bib24) 2016; 105 Berg (10.1016/S0140-6736(22)02076-1_bib29) 2021; 6 Packer (10.1016/S0140-6736(22)02076-1_bib30) 2021; 143 Butler (10.1016/S0140-6736(22)02076-1_bib3) 2021; 23 Bistola (10.1016/S0140-6736(22)02076-1_bib9) 2021; 23 Logeart (10.1016/S0140-6736(22)02076-1_bib8) 2022; 24 Carubelli (10.1016/S0140-6736(22)02076-1_bib10) 2021; 8 McDonagh (10.1016/S0140-6736(22)02076-1_bib16) 2022; 24 Kimmoun (10.1016/S0140-6736(22)02076-1_bib17) 2019; 21 Jaarsma (10.1016/S0140-6736(22)02076-1_bib20) 2008; 168 36463894 - Lancet. 2022 Dec 3;400(10367):1901-1903 36747103 - Nat Rev Cardiol. 2023 Apr;20(4):213-214 36877970 - Ann Intern Med. 2023 Mar;176(3):JC31 |
| References_xml | – volume: 46 start-page: 425 year: 2005 end-page: 431 ident: bib27 article-title: Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure publication-title: J Am Coll Cardiol – volume: 24 start-page: 219 year: 2022 end-page: 226 ident: bib8 article-title: Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF) publication-title: Eur J Heart Fail – volume: 24 start-page: 4 year: 2022 end-page: 131 ident: bib16 article-title: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC publication-title: Eur J Heart Fail – volume: 143 start-page: 326 year: 2021 end-page: 336 ident: bib30 article-title: Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial publication-title: Circulation – volume: 172 start-page: 1386 year: 2012 end-page: 1394 ident: bib6 article-title: The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries publication-title: Arch Intern Med – volume: 23 start-page: 1170 year: 2021 end-page: 1181 ident: bib9 article-title: Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum publication-title: Eur J Heart Fail – volume: 168 start-page: 316 year: 2008 end-page: 324 ident: bib20 article-title: Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) publication-title: Arch Intern Med – volume: 21 start-page: 1459 year: 2019 end-page: 1467 ident: bib17 article-title: Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study publication-title: Eur J Heart Fail – volume: 144 start-page: 1284 year: 2021 end-page: 1294 ident: bib32 article-title: Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial publication-title: Circulation – volume: 72 start-page: 351 year: 2018 end-page: 366 ident: bib4 article-title: Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry publication-title: J Am Coll Cardiol – volume: 318 start-page: 713 year: 2017 end-page: 720 ident: bib12 article-title: Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial publication-title: JAMA – volume: 28 start-page: 568 year: 2022 end-page: 574 ident: bib22 article-title: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial publication-title: Nat Med – volume: 384 start-page: 117 year: 2021 end-page: 128 ident: bib23 article-title: Sotagliflozin in patients with diabetes and recent worsening heart failure publication-title: N Engl J Med – volume: 23 start-page: 420 year: 2021 end-page: 431 ident: bib15 article-title: Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades publication-title: Eur J Heart Fail – volume: 22 start-page: 1472 year: 2020 end-page: 1482 ident: bib11 article-title: Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries publication-title: Eur J Heart Fail – volume: 105 start-page: 1021 year: 2016 end-page: 1029 ident: bib24 article-title: BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure publication-title: Clin Res Cardiol – volume: 121 start-page: 969 year: 2018 end-page: 974 ident: bib13 article-title: Effect of optimizing guideline-directed medical therapy before discharge on mortality and heart failure readmission in patients hospitalized with heart failure with reduced ejection fraction publication-title: Am J Cardiol – volume: 6 start-page: 499 year: 2021 end-page: 507 ident: bib29 article-title: Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction publication-title: JAMA Cardiol – volume: 78 start-page: 2004 year: 2021 end-page: 2012 ident: bib31 article-title: In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction publication-title: J Am Coll Cardiol – volume: 8 start-page: 2473 year: 2021 end-page: 2484 ident: bib7 article-title: Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of death publication-title: ESC Heart Fail – volume: 8 start-page: 1944 year: 2021 end-page: 1953 ident: bib10 article-title: Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure publication-title: ESC Heart Fail – volume: 23 start-page: 1981 year: 2021 end-page: 1982 ident: bib18 article-title: Amended STRONG-HF study design publication-title: Eur J Heart Fail – volume: 321 start-page: 753 year: 2019 end-page: 761 ident: bib19 article-title: Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the Pact-HF randomized clinical trial publication-title: JAMA – volume: 289 start-page: 712 year: 2003 end-page: 718 ident: bib28 article-title: Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study publication-title: JAMA – volume: 28 start-page: 1355 year: 2022 end-page: 1361 ident: bib2 article-title: Health system-level performance in prescribing guideline-directed medical therapy for patients with heart failure with reduced ejection fraction: results from the CONNECT-HF trial publication-title: J Card Fail – volume: 326 start-page: 314 year: 2021 end-page: 323 ident: bib21 article-title: Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients with heart failure with reduced ejection fraction: the CONNECT-HF randomized clinical trial publication-title: JAMA – year: 2022 ident: bib26 article-title: Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction publication-title: Circ Heart Fail – volume: 20 start-page: 345 year: 2018 end-page: 354 ident: bib14 article-title: Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study publication-title: Eur J Heart Fail – volume: 23 start-page: 1334 year: 2021 end-page: 1342 ident: bib3 article-title: Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event publication-title: Eur J Heart Fail – volume: 43 start-page: 908 year: 2021 end-page: 915 ident: bib5 article-title: The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy publication-title: Eur Heart J – volume: 133 start-page: e25 year: 2020 end-page: e31 ident: bib25 article-title: Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial publication-title: Am J Med – volume: 19 start-page: 1242 year: 2017 end-page: 1254 ident: bib1 article-title: Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry publication-title: Eur J Heart Fail – volume: 24 start-page: 4 year: 2022 ident: 10.1016/S0140-6736(22)02076-1_bib16 publication-title: Eur J Heart Fail doi: 10.1002/ejhf.2333 – volume: 143 start-page: 326 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib30 article-title: Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.051783 – volume: 78 start-page: 2004 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib31 article-title: In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2021.08.064 – volume: 23 start-page: 1334 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib3 article-title: Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event publication-title: Eur J Heart Fail doi: 10.1002/ejhf.2252 – volume: 318 start-page: 713 year: 2017 ident: 10.1016/S0140-6736(22)02076-1_bib12 article-title: Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.10565 – volume: 23 start-page: 420 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib15 article-title: Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades publication-title: Eur J Heart Fail doi: 10.1002/ejhf.2103 – volume: 46 start-page: 425 year: 2005 ident: 10.1016/S0140-6736(22)02076-1_bib27 article-title: Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.04.038 – volume: 289 start-page: 712 year: 2003 ident: 10.1016/S0140-6736(22)02076-1_bib28 article-title: Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study publication-title: JAMA doi: 10.1001/jama.289.6.712 – volume: 8 start-page: 2473 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib7 article-title: Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of death publication-title: ESC Heart Fail doi: 10.1002/ehf2.13369 – volume: 105 start-page: 1021 year: 2016 ident: 10.1016/S0140-6736(22)02076-1_bib24 article-title: BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure publication-title: Clin Res Cardiol doi: 10.1007/s00392-016-1014-9 – volume: 23 start-page: 1981 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib18 article-title: Amended STRONG-HF study design publication-title: Eur J Heart Fail doi: 10.1002/ejhf.2348 – volume: 22 start-page: 1472 year: 2020 ident: 10.1016/S0140-6736(22)02076-1_bib11 article-title: Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries publication-title: Eur J Heart Fail doi: 10.1002/ejhf.1869 – volume: 28 start-page: 568 year: 2022 ident: 10.1016/S0140-6736(22)02076-1_bib22 article-title: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial publication-title: Nat Med doi: 10.1038/s41591-021-01659-1 – volume: 8 start-page: 1944 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib10 article-title: Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure publication-title: ESC Heart Fail doi: 10.1002/ehf2.13223 – volume: 23 start-page: 1170 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib9 article-title: Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum publication-title: Eur J Heart Fail doi: 10.1002/ejhf.2219 – volume: 326 start-page: 314 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib21 article-title: Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients with heart failure with reduced ejection fraction: the CONNECT-HF randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.8844 – volume: 172 start-page: 1386 year: 2012 ident: 10.1016/S0140-6736(22)02076-1_bib6 article-title: The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries publication-title: Arch Intern Med doi: 10.1001/archinternmed.2012.3310 – volume: 133 start-page: e25 year: 2020 ident: 10.1016/S0140-6736(22)02076-1_bib25 article-title: Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial publication-title: Am J Med doi: 10.1016/j.amjmed.2019.06.053 – volume: 121 start-page: 969 year: 2018 ident: 10.1016/S0140-6736(22)02076-1_bib13 article-title: Effect of optimizing guideline-directed medical therapy before discharge on mortality and heart failure readmission in patients hospitalized with heart failure with reduced ejection fraction publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2018.01.006 – volume: 144 start-page: 1284 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib32 article-title: Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.056824 – volume: 24 start-page: 219 year: 2022 ident: 10.1016/S0140-6736(22)02076-1_bib8 article-title: Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF) publication-title: Eur J Heart Fail doi: 10.1002/ejhf.2357 – volume: 6 start-page: 499 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib29 article-title: Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2020.7585 – volume: 20 start-page: 345 year: 2018 ident: 10.1016/S0140-6736(22)02076-1_bib14 article-title: Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study publication-title: Eur J Heart Fail doi: 10.1002/ejhf.932 – volume: 384 start-page: 117 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib23 article-title: Sotagliflozin in patients with diabetes and recent worsening heart failure publication-title: N Engl J Med doi: 10.1056/NEJMoa2030183 – volume: 321 start-page: 753 year: 2019 ident: 10.1016/S0140-6736(22)02076-1_bib19 article-title: Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the Pact-HF randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2019.0710 – volume: 19 start-page: 1242 year: 2017 ident: 10.1016/S0140-6736(22)02076-1_bib1 article-title: Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry publication-title: Eur J Heart Fail doi: 10.1002/ejhf.890 – volume: 168 start-page: 316 year: 2008 ident: 10.1016/S0140-6736(22)02076-1_bib20 article-title: Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) publication-title: Arch Intern Med doi: 10.1001/archinternmed.2007.83 – volume: 72 start-page: 351 year: 2018 ident: 10.1016/S0140-6736(22)02076-1_bib4 article-title: Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.04.070 – volume: 43 start-page: 908 year: 2021 ident: 10.1016/S0140-6736(22)02076-1_bib5 article-title: The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy publication-title: Eur Heart J – volume: 21 start-page: 1459 year: 2019 ident: 10.1016/S0140-6736(22)02076-1_bib17 article-title: Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study publication-title: Eur J Heart Fail doi: 10.1002/ejhf.1575 – year: 2022 ident: 10.1016/S0140-6736(22)02076-1_bib26 article-title: Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction publication-title: Circ Heart Fail doi: 10.1161/CIRCHEARTFAILURE.121.009295 – volume: 28 start-page: 1355 year: 2022 ident: 10.1016/S0140-6736(22)02076-1_bib2 article-title: Health system-level performance in prescribing guideline-directed medical therapy for patients with heart failure with reduced ejection fraction: results from the CONNECT-HF trial publication-title: J Card Fail doi: 10.1016/j.cardfail.2022.03.356 – reference: 36877970 - Ann Intern Med. 2023 Mar;176(3):JC31 – reference: 36463894 - Lancet. 2022 Dec 3;400(10367):1901-1903 – reference: 36747103 - Nat Rev Cardiol. 2023 Apr;20(4):213-214 |
| SSID | ssj0004605 |
| Score | 2.7521777 |
| Snippet | There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.... Summary Background There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for... There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart... BackgroundThere is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1938 |
| SubjectTerms | Adverse events Angiotensin Blood pressure Brain natriuretic peptide Cardiology Cardiology and cardiovascular system Congestive heart failure Death Effectiveness Enzymes Female Health services Heart Failure Hospitals Human health and pathology Humans Laboratories Life Sciences Male Middle Aged Mineralocorticoid Receptor Antagonists - therapeutic use Minority & ethnic groups Missing data Mortality Patients Peptides Potassium Quality of Life Renin Risk Risk reduction Safety Stroke Volume Titration Treatment Outcome Ventricle Ventricular Function, Left |
| Title | Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673622020761 https://dx.doi.org/10.1016/S0140-6736(22)02076-1 https://www.ncbi.nlm.nih.gov/pubmed/36356631 https://www.proquest.com/docview/2744645173 https://www.proquest.com/docview/2735865088 https://inserm.hal.science/inserm-03934196 |
| Volume | 400 |
| WOSCitedRecordID | wos000923456100023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfohhAvfH8URmUkkDZpYflwnJQXNKaVPtCuagvqW-TYDlTaktImk_pH8T9yZyfZy8aQeDklTS5J5Z_vzr4vQt5liocyTV3HS1noMB_9uwo34FWfh5mMmGa22UQ0HseLRX9Sb7ht6rDKRiYaQa0KiXvkR1jJjrPQi4JPq18Odo1C72rdQqNDdrFKQmBC9ybX5UWaEPerDJ6jWfvjvu8fgM0Ucce7STd1fmKQ5E0WqNFEg4f_-x8ekQe1DUqPLWgekzs6f0LujWov-1PyeyYyXW4PaVmc67Ut5L2lIldUY8EJIbe0yGi1cgBpFkB4_qPCilnwAMeqSa3ohfUCUZvkBWtyCiYyFbIqNcVO2iXNxBLj4un-bD49G39xhoODj1RQE-bY7FMeUmzx5QBcNRyDblUFgFMr-D6cPc_It8Hp_GTo1G0dHAkTvgSpz6JQcVeA7aZczVWIXXjRwShBWHDsfyzcUMkUlGfMdcYkl1kgFKwstchkGjwnO3mR65eEwnIsk54AG0owloVYKlrAAigQWoOhE_W7hDUDmsi65jm23jhPrglu8_3E4CDxuuRDy7ayRT9uY-ANWpImoxVkcAJq6TbGuGWsTR47Rv_C-h5g2X4flgkfHn9NljmIrosEU64ZSNdLuG-vAWNSy6dNcoXELnnbXobBQ3eRyHVR4T1BGBsDvkteWMC3bwuwrCEPvFd_f_hrct_HdBEM_wn2yE65rvQbcldelsvNukc60fQ70kVkaAw0PvF6ZPfz6XgyhbORa-kcqT8y9MzQSc9M9T9Ud0nk |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF61BQEX3o9AgUWiUit1qR_rdYKEUAWEVE0CaoLU27LeXUOk1g6JU5QfBb-RGa_tXlrKpQdueXjWlneeOzPfEPIyNSLSSeIxP-ER4wHmdw0ewJuOiFIdc8vdsIl4OGwfHnY-r5DfdS8MllXWOrFU1CbXeEa-g0h2gkd-HL6d_mA4NQqzq_UIDccW-3b5E0K2-Zu997C_G0HQ_TB-12PVVAGmgd8KUDo8jozwFLgOxrPCRDgEFvNbGnhV4Phd5UVGJ6C728KmXAudhspAYGNVqpMQ1l0lVxBXD0sIB974rD7MsqT-tGNoZ9T8uBkEW-CjxYL559nC1e9YlHmex1tavu6t_-2d3SY3Kx-b7jqhuENWbHaXXBtUVQT3yK-RSm2x3KZFfmRnDqh8SVVmqEVADaWXNE_pYspAkpyA4PdvC0QEgwWYcwOsoccuy0VdE9vEzimEAFTpRWEpTgovaKomWPdPN0fjg0_Dj6zX3XpNFS3LOOtz2G2KI8wYiKOFz-A7mByEzxp4PtQO98mXS3lZD8halmf2EaEQbqbaV-AjKs7TCKGwFQR4obIWHLm40yK8ZiCpK0x3HC1yJM8o3gsCWfKd9FvkVUM2daAmFxGImjtl3bELNkaC2b2IsN0QVi6d26N_Id0AMWieD2HQe7t9OclANR9LbCnnYD1O4Lr1mvllpX_n8pTzW-RF8zdsHqbDVGbzBV4TRu0yQGmRh07AmruFCNsoQv_x3xd_Tq73xoO-7O8N95-QGwG2xmCpU7hO1orZwj4lV_VJMZnPnpWKgpKvly1lfwBbFZuQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bT9RAFJ4AGuKLd3EVdUwkgYSy23Y63TUxhoDrEnAlLiS8jdO56CbQrrstZn-Uf8Bf5zmdtryA-MKDb3vpmTad853LnBshb6zmkUqSjucnLPJYgPFdjQfwuscjq2JmmBs2EQ-H3ZOT3uEC-V3XwmBaZS0TS0GtM4Vn5G3sZMdZ5Mdh21ZpEYe7_feTHx5OkMJIaz1Ow7HIvpn_BPdt9m5vF_Z6LQj6H452Bl41YcBTwHs5CCAWR5p3JJgRumO4jnAgLMa6FPAtx1G8shNplYAc73JjmeLKhlKDk2OkVUkI6y6SW3EIXIxV6jv-ZTWZZXr9RfVQe9T8uB4EG2Cvxdzzr9KLi98xQfMq67fUgv17__P7u0_uVrY33XZgeUAWTPqQLH-qsgsekV8jaU0-36R5dmqmroH5nMpUU4ONNqSa08zSYuIBwhxw8Pu3AjuFwQKeMw-Mpmcu-kVdcdvYzCi4BlSqIjcUJ4jn1Mox1gPQ9dHRl8_Dj96gv_GWSlqmd9bns5sUR5t5AFMDn8Gm0BmA0mh4PpQaj8nxjbysJ2QpzVLzlFBwQ63yJdiOkjEbYYtsCY5fKI0BAy_utQirmUmoqtc7jhw5FZck9QWBKHlQ-C2y1ZBNXLOT6wh4zamiruQF3SNAHV9H2G0IK1PP7dG_kK4BJJrnw_bog-0DMU5BZJ8JLDVnoFXO4brVGgiiksszcYGCFnnd_A2bh2EymZqswGvCqFs6Li2y4sDW3C3Edo489J_9ffFXZBnAJQ72hvvPyZ0AK2YwAypcJUv5tDAvyG11no9n05elzKDk602D7A8SgKQO |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+tolerability+and+efficacy+of+up-titration+of+guideline-directed+medical+therapies+for+acute+heart+failure+%28STRONG-HF%29%3A+a+multinational%2C+open-label%2C+randomised%2C+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Mebazaa%2C+Alexandre&rft.au=Davison%2C+Beth&rft.au=Chioncel%2C+Ovidiu&rft.au=Cohen-Solal%2C+Alain&rft.date=2022-12-03&rft.issn=0140-6736&rft.volume=400&rft.issue=10367&rft.spage=1938&rft.epage=1952&rft_id=info:doi/10.1016%2FS0140-6736%2822%2902076-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S0140_6736_22_02076_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |